Table 2.

Survival in percentage by 5- and 10-year, stage, surgery, and screening detection group

	Detected on first screening				Detected on second or later screening				Interval cancer				Total
	5-year		10-year		5-year		10-year		5-year		10-year		5-year		10-year
	OS	BCSS	OS	BCSS	OS	BCSS	OS	BCSS	OS	BCSS	OS	BCSS	OS	BCSS	OS	BCSS
	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI
All early-stages
BCT	98 96–99	99 99–100	92 89–94	97 94–98	97 96–98	99 98–99	93 92–95	97 96–98	95 93–97	97 95–98	89 85–92	94 91–96	97 96–97	98 98–99	92 91–97	96 96–97
MTX	95 92–97	98 96–99	86 81–90	92 96–99	94 92–95	97 96–98	88 85–91	95 92–96	91 88–93	92 89–94	83 78–87	89 85–91	93 92–94	96 95–97	86 84–88	92 91–94
T1N0M0
BCT	98 96–99	99 99–100	93 89–95	97 94–98	98 97–98	99 99–100	95 93–96	98 97–99	96 93–97	98 95–99	89 84–93	95 91–97	97 97–98	99 99–99	93 92–95	98 97–98
MTX	95 92–97	99 96–100	87 82–91	94 90–97	94 92–96	98 96–99	89 85–92	96 93–98	97 93–99	100 –	91 83–95	96 89–99	95 94–96	99 98–99	89 86–91	96 93–97
T2N0M0
BCT	98 86–100	98 86–100	94 77–99	94 77–99	94 88–97	95 90–98	85 73–91	88 77–94	92 84–96	94 88–96	87 77–93	92 83–96	94 90–96	95 92–97	87 81–92	90 85–94
MTX	100 –	100 –	93 74–98	100 –	92 86–96	97 92–99	83 74–90	94 86–97	86 78–91	86 79–91	81 72–88	85 77–90	91 87–93	93 89–95	84 78–88	91 87–94
T1N1M0
BCT	98 93–100	99 94–100	88 78–94	98 90–99	98 95–99	99 96–99	94 95–99	98 96–99	97 90–99	97 90–99	92 81–97	94 85–98	98 97–99	99 97–99	92 88–95	97 94–99
MTX	96 83–99	100 –	86 68–94	93 74–98	93 88–95	96 90–98	87 78–93	91 82–95	92 83–96	93 85–97	79 65–88	85 72-93	93 90–96	96 92–98	84 78-89	89 83–93
T2N1M0
BCT	94 77–98	97 80–100	88 65–96	91 65–98	89 79–94	94 86–98	73 79–94	81 86–98	96 84–99	98 85–100	81 57–92	87 63–96	92 86–95	96 91–98	79 68–86	85 75–91
MTX	84 66–93	87 69–95	62 38–79	64 39–81	95 86–98	96 87–99	95 86–98	96 88–99	85 75–90	86 76–92	75 62–70	83 72–82	88 83–92	90 85–95	80 71–86	84 77–90